valu usd unless otherwis note
view continu make progress regard remedi
north campu separ fda recent inspect issu new
form west campu eight observ
form letter west campu appear much less oner
origin form letter compani north campu
new form letter issu west campu
facil legaci zimmer facil warsaw oct
recent inspect west campu yield form observ
vs observ north campu inspect
observ west campu inspect
west campu observ observ repeat observ
previou inspect oct howev length
recent form letter west campu page
significantli less recent north campu letter page
compar west campu inspect page
continu make progress resolv form
north campu novemb provid fifth updat
fda regard remedi origin form fda
north campu inspect estim complet
action implement phase capa fifth updat
vs fourth updat third updat
second updat estim verifi
effect close capa fifth updat vs
fourth updat third updat feel free
email us copi new west campu form well
fifth updat fda north campu
lower ep estim stick
turnaround play despit shape soft
recon market believ consensu estim
still appear reason north campu product met manag
target expect manag provid guidanc
could hear new ceo bryan hanson provid qualit commentari
could caus downward revis sell-sid estim ahead
tuesday earn call lower ep estim
flat y/i fce better account increas invest
special sale rep perform incent plan headwind
continu remedi cost still recommend longer-
term investor believ recent hire bryan hanson go
long way rebuild investor employe custom confid
howev patienc need new manag come board
reinvest busi new knee/should product launch
ramp throughout
price prior trade day market close estimate unless otherwis note
believ share outperform
peer group follow key reason
believ world-wide recon market larg stabl
given recent commentari orthoped manag
team well orthoped surgeon survey
believ world-wide recon market larg stabl
fact world-wide recon market growth remain
stabl y/i rang everi year
expect stabl world-wide recon trend continu
 job outlook overal economi continu
slowli improv price pressur remain constant
y/i rang includ mix
recent acquisit upcom new product launch
focus fill portfolio gap acceler top-line
growth addit ldrh expand zbh mi portfolio
add fastest-grow cervic disc market
share put compani within strike distanc
separ acquisit med-tech
sa provid robot play orthoped
market final note sever import
launch acceler
cementless knee persona revisis system stemless
recent leadership chang unlock valu
share long-term patienc need manag
near-term focu continu remedi issu
north campu regain confid surgeon
custom focu vital project fill key
product gap acceler top-line growth expect
anoth peer group growth year
top bottom-lin await outcom
reinspect north campu could
occur year-end
bloomberg capit market estim upside/downside/target
base case scenario price target assum
compani grow top-line in-line market growth rate
medium term assum fda
issu warn letter north campu
base case scenario appli multipl peer
pro-forma adjust dilut cash ep estim
scenario model long-term adjust
cash ep growth slightli peer high-single-digit y/
rang analysi support outperform rate
upsid scenario assum return
top-line growth suppli concern resolv
compani regain surgeon confid launch new
product scenario also assum compani new
ceo bring addit experi medic devic manag
help lead compani also explor potenti
divestitur sever under-perform busi includ
dental scenario long-term adjust dilut
ep growth could slightli larg cap md
downsid scenario assum compani
grow top-line well market growth rate
owe continu recon share loss on-going pressur
dental bone heal spine busi addit
assum fall short year synergi target
biomet final call pure price
world-wide recon market take anoth step
mid-single-digit y/i large-cap md
obtain copi fifth updat fda regard north campu
novemb well new form issu west campu pleas contact
us copi overal research indic continu make progress
regard remedi north campu although fda reinspect may occur
separ fda recent inspect issu new form west
campu eight total observ five repeat observ
form letter west campu appear much less oner origin form
letter compani north campu
new form letter issu west campu
three fda investig inspect west campu facil legaci zimmer facil
warsaw octob recal manufactur class devic
zbh manufactur facil subject mandatori biennial inspect law zbh last
west campu inspect occur octob worth note
two three fda investig also inspect compani north campu
respons issu oner expect form letter
north campu one three fda investig remain unchang prior
inspect west campu recent inspect west campu yield form
observ vs observ origin north campu inspect
also compar observ compani receiv fda inspect
west campu facil exhibit addit detail observ
west campu observ observ observ
repeat observ previou west campu facil inspect oct
recal observ west campu facil inspect repeat
observ repeat observ compani west campu
facil inspect accordingli still work left resolv prior issu fda
west campu howev length form letter west campu
page significantli less origin north campu letter page larg
compar west campu inspect page addit complex
length west campu inspect day inspect much less north
campu inspect day inspect even less west campu inspect
exhibit list observ describ fda recent letter octob regard zbh west
observ repeat observ process whose result fulli verifi subsequ inspect test adequ valid accord establish proceduresfirm identifi appropri scope need correct prevent recurr nonconform product per correct prevent action process sop adequ establish control product conform specifi requirementsa product found contamin inspect final clean oper document use nonconform reportb nonconform document use nonconform report per exist repeat observ devic packag and/or ship contain design construct protect devic alter damag process storag handl distributionfirm packag develop condit test guidanc procedur provid adequ assur packag system provid physic protect maintain integr steril barrier system normal anticip hazard associ monitor control process paramet valid process adequ establish issu evalu open statist process control spc control chart show process monitor data drift outsid establish control use part qualiti system adequ valid intend use accord establish protocolvalid softwar use determin scope qualiti hold perform per comput system valid repeat observ procedur ensur equip routin calibr adequ establishedfirm calibr procedur ensur piec equip calibr repeat observ procedur receiv review evalu complaint formal design unit adequ establishedfirm complaint handl procedur contain mechan employe determin complaint receiv firm made void repeat observ written mdr procedur implementedprocedur number ensur mdr seriou injuri report requir exhibit list observ describ fda previou letter octob regard zbh west
observ repeat observ sampl plan base valid statist repeat observ procedur correct prevent action adequ repeat observ procedur adequ establish control product conform specifi repeat observ process whose result fulli verifi subsequ inspect test valid accord establish repeat observ test/measur equip found meet accuraci precis limit inadequ action taken evalu whether advers effect devic repeat observ devic packag and/or ship contain design construct protect devic alter damag process storag handl repeat observ procedur design valid adequ repeat observ design output document repeat observ procedur receiv review evalu complaint formal design unit written mdr procedur includ intern system provid standard review process/procedur determin event meet criteria report exhibit list inspect date outcom fda inspect zbh warsaw north west campus
continu make progress resolv form
north campu
novemb provid fifth updat fda regard remedi
origin form fda north campu inspect recal compani last updat
fourth updat occur juli compani spent complet root
cause/act plan current action implement phase
correct prevent action capa part process involv compani
implement numer interim control immedi contain mitig action
includ increas process monitor valid process novemb updat
fda suggest eight interim control current remain place plan
convert standard procedur throughout addit compani complet
network-wid corpor audit zimmer biomet site end-of-lin oper
clean steril packag steril assess issu identifi fda
inspect warsaw north campu network-wid audit complet
site june final individu site audit report issu juli
network-wid summari report issu august
inspect end date/d issuancesiteeventmarch west indianainspectionnovemb north indianainspectioninspect citat and/or north indianainspectionjuli west indianainspectioninspect citat and/or west indianainspectioninspect citat and/or west indianainspectioninspect citat and/or west indianainspectionfebruari west indianainspectioninspect citat and/or west indianainspectioninspect citat and/or north indianainspectioninspect citat and/or west indianainspectioninspect citat and/or north indianainspectioninspect citat and/or west indianainspectioninspect citat and/or medic suppli devic
overal estim complet action implement phase
capa fifth updat vs fourth updat third updat
second updat estim verifi effect
close capa fifth updat vs fourth updat
third updat given remedi progress believ fda
reinspect north campu may occur howev believ
reinspect north campu like still occur year-end
exhibit list observ describ fda origin letter novemb regard zbh north
observ repeat observ process whose result fulli verifi subsequ inspect test adequ valid accord establish control environment condit adequ adequ establish control product conform specifi design control correct prevent action adequ control procedur describ process control necessari ensur conform specif adequ repeat observ procedur monitor control process paramet valid process adequ receiv review evalu complaint formal design unit adequ accept activ adequ suitabl design perform necessari plan base valid statist rework nonconform product adequ ensur purchas otherwis receiv product servic conform specifi requir adequ control procedur adequ establish exhibit zbh progress outstand observ outlin compani letter fifth updat
letter updat fifth updat fda
observ open capa date root cause/act complet date complet action implement phase complet date complet verifi effect close capa date exhibit zbh progress outstand observ outlin compani letter fifth updat
letter updat fifth updat fda
expect result earn call
recon market appear come bit softer previous thought
syk overal orthoped perform in-line expect howev
 knee perform y/i expect suggest compani
gain traction mako continu benefit cementless knee offer
zbh suppli issu jnj world-wide recon perform came expect
like share loss knee share gain hip believ lose share knee
issu attun attun revis platform fulli roll yet
share loss robot knee player syk pre-announce jnj full
result estim world-wide recon market grew y/i constant
currenc rang addit encourag jnj commentari regard
 hospit surgic procedur recal estim overal hospit
surgic procedur show improv
despit softer recon market believ consensu recon number
believ snn remain share gainer world-wide recon market
share loss continu come lesser extent said street
expect guidanc low zbh recon busi recal manag
expect constant currenc revenu growth rate total compani rang
inclus contribut sell day impact compar
prior year period therefor zbh bill day adjust constant currenc growth rate
expect rang recon assum y/i
constant currenc declin zbh world-wide recon busi estim assum
hit revenu growth hit recent indian knee price reduct
vs hit recon growth estim impli total hip/kne revenu
vs fce still look achiev suppli constrain
right depend product output versu market growth view
manag said recent investor confer product north campu
target shoot overal model
revenu y/i constant currenc fce adjust cash ep
vs manag guidanc fce
exhibit estim vs consensu
inc perform delta usd except per-shareactualrbc estimatefc estimateorthoped extrem gross sg oper expens pre-tax tax incom includ non-control share fulli medic suppli devic
expect go forward zbh new ceo
lower ep estim orthoped market growth
slow believ zbh new ceo need reinvest expect
drive top-line growth
saw slow world-wide recon growth world-wide spine market growth
expect world-wide recon growth y/i constant currenc
separ expect world-wide spine growth y/i
constant currenc high deduct commerci
reimburs pressur spine gener declin inpati surgic procedur
procedur delay hurrican cite reason recent slower growth
unfortun market repres compani total sale given
on-going remedi effort compani slow orthoped market growth
believ zbh new ceo bryan hanson need spend previous expect
drive top-line growth exampl expect invest special sale rep
sport medicin extrem trauma take better advantag compani
divers product portfolio area see low risk way increas zbh
exposur faster grow market addit believ mr hanson want expand
zbh global footprint feel compani may reliant market
separ expect improv suppli manag previous said expect
get back full suppli product drive acceler revenu growth
particularli compani perform incent bonu plan fulli
fund like wont hit full year number howev look
restor program creat anoth potenti ep headwind addit
increment special sale rep invest well on-going remedi
cost recal expect spend remedi cost alon given
headwind lower adjust cash ep estim flat y/i
vs fce adjust cash ep estim also move lower
y/i fce maintain price target impli
adjust cash ep estim adjust ebitda estim
expect manag give offici guidanc earn call
expect guidanc conserv
new presid ceo bryan hanson join decemb
expect compani provid full year guidanc earn call
januari believ manag could provid qualit commentari
put take could caus downward revis sell-sid ep estim
expect manag provid guidanc guidanc conserv
mr hanson like want overpromis deliv first quarter zbh
ceo continu model revenu y/i constant currenc fce
model assum improv zbh sale trend
current view reason bottom-lin model adjust
cash ep y/i fce
write wall zbh dental busi view expect
busi divest
recent competitor confer mr hanson said compani current focus
hip knee see great opportun growth zbh sport
medicin extrem trauma busi believ leverag
exist relationship brand gain greater traction combin zimmer
biomet product portfolio mr hanson said see obviou connect
zbh spine cmf busi come decision-mak believ
connect across busi technolog standpoint exampl
believ invest compani make robot use gener return
spine cranial piec cmf busi notabl absent ceo recent
strategi discuss competitor confer compani dental busi believ
busi leverag compani exist orthoped relationship
leverag meaning invest compani make robot accordingli
see busi ripe divest help acceler compani debt
worth note recent senior manag reorgan could signal
futur zbh dental busi decemb aur bruneau announc
new group presid spine cmf thorac surgeri assist robot
previou group head adam johnson respons spine dental bone
heal cmf thorac mr johnson leav chri jefferi announc
interim group presid spine dental cmf thorac move bone heal
leadership david nolan howev far tell dental
leadership aur bruneau david nolan could give us insight
manag think futur zbh dental busi
ultim expect dental busi divest busi gener
annual revenu believ ebit margin high low recent
larg dental deal gone ev/last month sale rang
ev/last month ebitda rang howev note premium dental asset zbh
dental busi declin past year may garner high
valuat believ reason valuat rang zbh dental busi
exhibit recent larg dental implant deal enterpris valu
stick turnaround play
tough last month remedi effort led acceler
 recon share loss allow compani sale rep go
offens post biomet deal close howev recent hire bryan hanson presid
ceo go long way rebuild investor employe custom confid investor
spoken last sever week market still appear uncertain whether
buy today wait compani result futur guid recal
expect provid guidanc earn call januari
expect qualit commentari lead downward revis street ep estim
question remain whether investor give mr hanson pass potenti
lower number invest versu later turnaround stori continu
recommend long-term investor patienc need new manag come
board reinvest busi tax reform benefit reinvest back
busi work solv culture/mor issu within organ new
knee/should product launch ramp throughout
deriv price target appli multipl pro-forma adjust
dilut cash ep estim large-cap med-tech peer
believ discount multipl appropri given lower top-lin growth rel
peer uncertainti regard on-going manufacturing/suppli issu price target
support outperform rate
risk rate price target
impedi achiev price target rate includ company-specif risk
suspens delay launch new product normal industri risk includ
competit depend agent distributor currenc intellectu properti
reimburs slow compani end market clinic trial risk regulatori
inc design develop manufactur market reconstruct
orthopaed implant includ small/larg joint dental spinal implant trauma
product sport medicin product relat orthopaed surgic product
sport extrem trauma
interest expens net
net incom attribut zmh
sport extrem trauma
